CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab

J Neurol Neurosurg Psychiatry. 2022 Aug;93(8):911-912. doi: 10.1136/jnnp-2021-327992. Epub 2022 Jan 27.

Authors

Simone de Vries Lentsch¹, Linda Al-Hassany², Michel Dominique Ferrari^#¹, Gisela Marie Terwindt^#¹, Antoinette MaassenVanDenBrink^#³

Affiliations

¹ Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
² Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
³ Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands a.vanharen-maassenvandenbrink@erasmusmc.nl.

^# Contributed equally.

PMID: 35086941
DOI: 10.1136/jnnp-2021-327992

No abstract available

Keywords: migraine; trigeminal nerve.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Calcitonin Gene-Related Peptide*
Humans
Migraine Disorders* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
erenumab
Calcitonin Gene-Related Peptide